GE HealthCare
GEHC
$72.91
-1.14%
GE HealthCare Technologies Inc. is a leading global medical technology company operating in the healthcare sector, primarily focused on imaging and ultrasound equipment, advanced visualization solutions, patient care solutions, and pharmaceutical diagnostics. The company is a market leader in medical imaging, distinguished by its strong brand heritage from General Electric, a diverse product portfolio, and a significant recurring revenue base from services and consumables. The current investor narrative centers on its performance as a newly independent public entity following its spin-off, with attention on navigating a challenging demand environment for capital equipment, as evidenced by recent revenue declines, while simultaneously executing its strategy to leverage AI and digital solutions to drive future growth and margin expansion.…
GEHC
GE HealthCare
$72.91
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. The core thesis is that GEHC is a fundamentally challenged market leader trading at a discounted valuation, creating a balanced risk/reward profile that favors patience over immediate conviction.
Supporting this view, the stock's forward P/E of 12.64x is deeply discounted relative to its trailing multiple and suggests the market has priced in significant pessimism. Analyst consensus expects a strong earnings recovery to an average EPS of $7.11. Furthermore, the company's robust TTM free cash flow of $1.5 billion and solid balance sheet (current ratio 1.18) provide a margin of safety. However, these positives are counterbalanced by severe fundamental headwinds, including a 12% YoY revenue decline and a 75% drop in Q4 net income.
The thesis would upgrade to a Buy if revenue stabilizes and shows sequential growth, or if the forward P/E compresses further toward 10x on sustained earnings delivery. It would downgrade to a Sell if revenue decline accelerates beyond 15% YoY or if net margins fail to recover above 8%. Currently, the stock appears fairly valued relative to its near-term challenges but undervalued relative to its long-term market position and cash-generating ability, making it a Hold for existing investors but not yet a compelling Buy for new money.
Sign up to view all
GEHC 12-Month Price Forecast
The assessment is neutral with medium confidence. GEHC presents a classic 'show me' story where compelling valuation (12.64x forward P/E) clashes with deteriorating fundamentals. The high-conviction, tight-range analyst EPS forecasts provide a clear benchmark for success or failure. The stance would upgrade to bullish on concrete evidence of revenue stabilization and margin recovery in the next 1-2 quarters. It would turn bearish if the stock breaks below $57.65 support or if forward earnings estimates begin to be revised downward materially. The high free cash flow and leading market position prevent a more negative view despite the clear operational headwinds.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $94.78 and implied upside of +30.0% versus the current price.
Average Target
$94.78
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$58 - $95
Analyst target range
GEHC is covered by 11 analysts, and recent institutional ratings show a predominantly bullish sentiment with actions like 'Buy', 'Overweight', and 'Outperform' from firms including BTIG, Wells Fargo, Stifel, and Evercore ISI, alongside 'Neutral' or 'Equal Weight' ratings from Citigroup, Barclays, and Morgan Stanley. The consensus recommendation leans bullish, though a precise average target price and implied upside cannot be calculated from the provided data which includes estimated EPS and revenue but not a specific price target. The analyst EPS estimates for the coming period show a tight range, with a low of $6.93, an average of $7.11, and a high of $7.24, indicating strong conviction on the bottom-line forecast. The recent pattern of reiterated ratings following earnings suggests analysts are maintaining their views post-results, but the lack of a wide target price spread in the available data limits the assessment of underlying uncertainty in the business outlook.
Bulls vs Bears: GEHC Investment Factors
The evidence currently tilts bearish, as deteriorating fundamentals (12% revenue decline, 75% net income drop) and severe negative price momentum outweigh the stock's attractive valuation and strong cash flow. The most critical tension in the investment debate is whether GEHC's significant forward P/E discount of 12.64x correctly anticipates a robust earnings recovery in line with tight analyst estimates ($7.11 avg EPS), or if it merely reflects a 'value trap' where persistent demand weakness and margin pressure prevent such a rebound. The resolution of this tension—specifically, the stabilization of revenue and a return to double-digit net margins—will determine the stock's direction.
Bullish
- Strong Free Cash Flow Generation: GEHC generated $1.506 billion in TTM free cash flow, providing significant internal funding capacity for investments, debt reduction, or shareholder returns. This robust cash generation, alongside a manageable debt-to-equity ratio of 0.96, provides a solid financial foundation despite earnings volatility.
- Attractive Forward Valuation: The stock trades at a forward P/E of 12.64x, a significant discount to its trailing P/E of 17.97x, implying the market expects a substantial earnings recovery. This forward multiple is near the lower end of the stock's historical P/E range, suggesting pessimism is largely priced in.
- Analyst Conviction on Earnings Recovery: Analyst EPS estimates for the coming period show a tight range ($6.93 low to $7.24 high), indicating strong conviction in the bottom-line forecast. This consensus, coupled with a predominantly bullish institutional rating sentiment, suggests professional confidence in a turnaround from the recent Q4 net income plunge to $184 million.
- Recurring Revenue Base & Market Leadership: Approximately half of GEHC's revenue is recurring from services, diagnostics, and digital solutions, providing stability. The company maintains a leading market share in imaging and ultrasound, supported by a strong global brand and diverse geographic footprint.
Bearish
- Severe Fundamental Deterioration: Q4 2025 revenue declined 12.13% YoY to $4.674B, and net income plummeted 75% to $184M, with net margin collapsing to 3.94% from 13.54%. This sharp deceleration and profit compression indicate significant operational and demand headwinds in its capital equipment business.
- Intense Negative Momentum & Underperformance: The stock is down 15.06% over the past 3 months and 11.35% over the past year, severely underperforming the S&P 500 by -11.06 and -33.55 percentage points, respectively. Trading just 22% above its 52-week low of $57.65, the price action reflects accelerating investor pessimism and a breakdown in technical support.
- High Volatility & Elevated Beta: With a beta of 1.305, GEHC is approximately 30% more volatile than the broader market, amplifying downside risk during market corrections. This high volatility, combined with a short ratio of 3.25, indicates significant speculative pressure and potential for further downside momentum.
- Margin Pressure & Profitability Erosion: Gross margin has shown high volatility, dipping to 39.99% on a trailing basis from 54.30% in the year-ago Q4, signaling cost and pricing pressures. The sharp decline in operating and net margins raises questions about the sustainability of the company's profitability model in the current environment.
GEHC Technical Analysis
The prevailing price trend for GEHC is a pronounced downtrend, with the stock down 11.35% over the past year and trading near the lower end of its 52-week range. The current price of $70.35 sits just 22% above its 52-week low of $57.65, indicating the stock is in a zone that could represent a value opportunity but also reflects significant negative momentum and investor pessimism. Recent short-term momentum has been decisively negative and accelerating, with the stock down 9.96% over the past month and 15.06% over the past three months, sharply underperforming the broader market as indicated by relative strength figures of -5.68 and -11.06, respectively. This severe near-term weakness suggests the longer-term downtrend is intensifying, likely driven by fundamental disappointments rather than a temporary pullback. Key technical levels are clearly defined, with immediate support at the 52-week low of $57.65 and resistance far above at the 52-week high of $89.77. A breakdown below the $57.65 support would signal a new leg down and likely trigger further selling, while a sustained move above recent highs near $88 would be needed to suggest a trend reversal. The stock's beta of 1.305 indicates it is approximately 30% more volatile than the broader market, which amplifies both downside and upside moves and is a critical factor for risk-aware position sizing.
Beta
1.30
1.30x market volatility
Max Drawdown
-32.1%
Largest decline past year
52-Week Range
$58-$90
Price range past year
Annual Return
+12.2%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | +0.4% |
| 3m | -16.5% | -2.0% |
| 6m | +2.7% | +4.1% |
| 1y | +12.2% | +23.9% |
| ytd | -12.0% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
GEHC's revenue trajectory shows clear signs of deceleration and contraction, with Q4 2025 revenue of $4.674 billion representing a 12.13% year-over-year decline. This follows a sequential decline from Q3's $5.143 billion, indicating weakening demand trends as the year progressed. The company's largest segment, Imaging, generated $4.901 billion, but the overall trend points to pressure across its capital equipment businesses. Profitability has deteriorated significantly, with Q4 2025 net income plunging to $184 million from $720 million in the year-ago quarter, and the net margin compressing to 3.94% from 13.54%. Gross margin also showed volatility, dipping to 39.99% on a trailing basis from 54.30% in the prior-year Q4, highlighting cost and pricing pressures. The balance sheet and cash flow position remains a relative strength, with a debt-to-equity ratio of 0.96 indicating a manageable leverage level and TTM free cash flow of $1.506 billion providing solid internal funding capacity. The current ratio of 1.18 suggests adequate short-term liquidity, and an ROE of 20.08%, while down from recent quarters, still reflects decent returns on shareholder equity, supported by the company's asset-light service and diagnostics segments.
Quarterly Revenue
$4.7B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given GEHC's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 17.97x and a forward PE of 12.64x based on analyst estimates. The significant discount of the forward multiple implies the market expects a substantial recovery in earnings over the next twelve months. Compared to sector averages, GEHC's valuation presents a mixed picture; its trailing PE of 17.97x is below the typical premium for medtech leaders but its Price-to-Sales ratio of 1.82x and EV/EBITDA of 11.34x need industry benchmarks for precise premium/discount analysis, though the forward PE discount suggests the market is pricing in challenges. Historically, the stock's current trailing PE of 17.97x is well below its own historical range observed in recent quarters, which has seen peaks above 50x (Q4 2025) and lows near 12x (Q4 2024). Trading near the lower end of its historical PE band suggests the market has already priced in significant pessimism, potentially creating a value opportunity if the company can stabilize its fundamentals, but it also reflects genuine concerns about earnings degradation.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on severe earnings volatility and margin compression. Q4 net income fell 75% YoY to $184M, and the net margin collapsed to 3.94% from 13.54%, indicating high sensitivity to demand cycles and cost inflation. While leverage is manageable (D/E of 0.96) and cash flow strong ($1.5B FCF), the company remains dependent on a recovery in capital equipment spending to justify its valuation. Revenue concentration in the cyclical Imaging segment (~45% of sales) adds to earnings volatility risk.
Market & Competitive Risks include valuation compression and sector rotation. Trading at a forward P/E of 12.64x, the stock is priced for a recovery; failure to deliver could lead to multiple contraction towards its 52-week low valuation. The high beta of 1.305 makes the stock vulnerable to broad market downturns, as evidenced by its severe underperformance (-33.55% relative strength vs. SPY over 1 year). Competitive threats are highlighted by news of rivals like RadNet aggressively investing in AI, potentially eroding GEHC's technological edge in advanced visualization.
Worst-Case Scenario involves a continuation of the current downtrend where demand weakness persists, margins fail to recover, and the stock breaks key technical support. This could trigger a re-rate to a deeper discount, with the price revisiting the 52-week low of $57.65. From the current price of ~$70.35, this represents a realistic downside of approximately -18%. A more severe scenario, incorporating further earnings misses and loss of market share, could push the stock below $57.65, approaching the maximum drawdown level of -34% observed recently.
FAQ
The key risks are, in order of severity: 1) Fundamental Deterioration Risk: Continued revenue declines and margin pressure, as seen in Q4 with a 12.1% sales drop and net margin collapse to 3.94%. 2) Market & Volatility Risk: A high beta of 1.305 amplifies losses in a down market, and the stock has severely underperformed the S&P 500 by over 33 percentage points in the past year. 3) Execution & Competitive Risk: Failure to stabilize the business or losing share in core imaging markets to rivals investing in AI, as indicated by recent industry news. 4) Valuation Compression Risk: If the earnings recovery fails, the forward P/E multiple could contract further, pushing the stock toward its 52-week low.
The 12-month forecast is bifurcated, with a 60% probability Base Case target range of $72-$82, a 25% probability Bull Case of $85-$95, and a 15% probability Bear Case of $57-$65. The Base Case, which is most likely, assumes a slow recovery where earnings meet the analyst consensus average of $7.11, supporting the current forward P/E multiple. The forecast hinges almost entirely on whether GEHC can arrest the severe revenue decline (-12.1% YoY in Q4) and restore profitability toward historical levels. The tight range of analyst EPS estimates ($6.93-$7.24) suggests professional forecasts are clustered around this recovery narrative.
GEHC appears fairly valued to slightly undervalued based on forward earnings potential, but overvalued relative to its recent deteriorating fundamentals. The forward P/E of 12.64x is a significant discount to its trailing P/E of 17.97x and suggests the market is pricing in a meaningful earnings recovery. Compared to its own historical P/E range, which has seen peaks above 50x, the current multiple is near the lower end. The valuation implies the market expects GEHC to overcome its current cyclical headwinds and return to profit growth, making it a discount if successful, but a potential value trap if not.
GEHC is a speculative buy for investors with a higher risk tolerance and a 2-3 year horizon. The forward P/E of 12.64x offers an attractive entry point if the company can execute an earnings recovery to the analyst consensus of $7.11 EPS. However, it is not a good buy for risk-averse or short-term investors, given the severe 12% revenue decline, 75% net income drop in Q4, and the stock's high volatility (beta 1.305). The biggest near-term risk is a further deterioration in demand, potentially pushing the stock toward its 52-week low of $57.65 (-18% downside).
GEHC is unsuitable for short-term trading due to its high beta (1.305) and negative momentum, which increase the risk of sharp losses. It is better suited for a long-term investment horizon of 3+ years, allowing time for its cyclical business to recover, for its AI and digital strategy to bear fruit, and for its valuation discount to potentially normalize. The minimal dividend yield (0.17%) indicates it is not an income stock. Given the current 'show me' phase of the story, investors must be prepared for volatility and possess the patience to hold through a potentially extended turnaround period.